Metastatic biopsy programmes combined with advances in genomic sequencing have
provided new insights into the molecular landscape of castration-resistant prostate cancer …

Prostate cancer (PCa) is globally the second most diagnosed cancer type and the most
common cause of cancer-related deaths in men. Family history of PCa, hereditary breast …

PURPOSE Germline testing (GT) is a central feature of prostate cancer (PCA) treatment,
management, and hereditary cancer assessment. Critical needs include optimized …

Prostate cancer ranks fifth in cancer-related mortality in men worldwide. DNA damage is
implicated in cancer and DNA damage response (DDR) pathways are in place against this …

Objective Evidence shows that gene mutation is a significant proportion of genetic factors
associated with prostate cancer. The DNA damage response (DDR) is a signal cascade …

Inherited genetic mutations can significantly increase the risk for prostate cancer (PC), may
be associated with aggressive disease and poorer outcomes, and can have hereditary …

The introduction of PARP inhibitors (PARPi) in prostate cancer is a milestone and provides a
pathway to hope in fighting this disease. It is the first time that drugs, based on the concept of …

Genetic testing for prostate cancer is rapidly growing and is increasingly being driven by
precision medicine. Rates of germline pathogenic variants have been reported in up to 15 …

Background The risk of high-grade prostate cancer, given a family history of cancer, has
been described in the general population, but not among men selected for prostate biopsy in …

Metastatic castration-resistant prostate cancer (mCRPC) encompasses a heterogeneous
wide range of molecular tumor behavior and a high risk of progression. Early detection and …